According to Regeneron Pharmaceuticals's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7.39378. At the end of 2023 the company had a P/S ratio of 7.29.
Year | P/S ratio | Change |
---|---|---|
2023 | 7.29 | 13.02% |
2022 | 6.45 | 52.74% |
2021 | 4.23 | -30.35% |
2020 | 6.07 | 0.56% |
2019 | 6.03 | -0.56% |
2018 | 6.07 | -11.8% |
2017 | 6.88 | -13.65% |
2016 | 7.97 | -42.46% |
2015 | 13.8 | -7.11% |
2014 | 14.9 | 14.33% |
2013 | 13.0 | 7.97% |
2012 | 12.1 | 4.9% |
2011 | 11.5 | 79.99% |
2010 | 6.39 | 23.67% |
2009 | 5.17 | -15.68% |
2008 | 6.13 | -59.74% |
2007 | 15.2 | -26.38% |
2006 | 20.7 | 52.6% |
2005 | 13.6 | 358.56% |
2004 | 2.96 | -79.13% |
2003 | 14.2 | -62.2% |
2002 | 37.5 | -33.51% |
2001 | 56.3 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 3.79 | -48.80% | ๐บ๐ธ USA |
Novartis NVS | 3.90 | -47.29% | ๐จ๐ญ Switzerland |
Amgen AMGN | 5.14 | -30.52% | ๐บ๐ธ USA |
Sanofi SNY | 2.44 | -67.01% | ๐ซ๐ท France |
Biogen BIIB | 3.09 | -58.17% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | 9.93 | 34.29% | ๐บ๐ธ USA |